Home›People›Bosun Hau
BH

Bosun Hau

Director at Allotera Therapeutics.

Director
Updated Nov 10, 2026·Latest SEC filing Jul 23, 2026·Suggest an edit

About Bosun Hau

Bosun Hau is a director at Allotera Therapeutics.

Bosun Hau first appears on SEC filings in 2021.

Experience

This experience comes from Bosun Hau's profile and from SEC filings. For roles taken from filings, the years are when the filings name Bosun Hau in the role, so the role may have started earlier or lasted longer.

D&D Pharmatech Current
Board Observer | Lead Investor
2025 – Present
SkyCell AG Current
Board Director | Investor
2024 – Present
Clove Dental Current
Non Executive Director | Investor
2022 – Present
Allotera Therapeutics, Inc. Current
Board Director | Lead Investor
2021 – Present · St. Louis, MO
Develops donor-cell therapies for people with blood cancers.
Kopi Kenangan Current
Board Director | Lead Investor
2021 – Present
Z-Alpha Therapeutics Current
Chairman | Founding Investor
2020 – Present
Tybourne Capital Management Current
Co-Founder & Managing Partner, Tybourne Strategic Opportunities Fund (TSOF) | Portfolio Manager
2019 – Present
MoMo (M_Service) Current
Investor
2019 – Present
Forte Biosciences, Inc.
Lead Investor
2023 – 2026
jinjer株式会社
Lead Investor
2022 – 2024
Lunit
Board Observer | Investor
2021 – 2023
LianBio
Board Observer | Investor
2020 – 2021
Paidy
Board Director | Lead Investor
2019 – 2021
Zentalis Pharmaceuticals
Board Observer | Lead Investor
2020
Bicycle Therapeutics
Non Executive Director | Investor
2019 – 2020
Evolus
Board Director | Lead Investor
2018 – 2020
Sailing Capital
Senior Advisor
2015 – 2020
Impossible Foods
Board Observer | Lead Investor
2018 – 2019
AbelZeta
Board Director | Lead Investor
2018 – 2019
MVM Partners
Partner
2009 – 2015

Key Colleagues at Startups

The people Bosun Hau works with at each company, as listed on that company's latest Form D.

Allotera Therapeutics, Inc. · Form D/A, Jul 23, 2026
DD
KL
Kevin Li
Director
NM
ND
Kumar Srinivasan
Kumar Srinivasan
President & Chief Executive Officer, director
Matthew Cooper
Matthew Cooper
Co-Founder & Chief Scientific Officer
Cherry Thomas
Cherry Thomas
Chief Medical Officer
Ayman Kabakibi
Ayman Kabakibi
Chief Operating Officer & EVP, R&D
BM

Sources

  1. SECAllotera Therapeutics, Inc. Form D/A, filed Jul 23, 2026